INVA vs NAGE: fair value comparison
Innoviva, Inc. and Niagen Bioscience, Inc. · Updated 2026-08-31
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, INVA currently sits closer to the top of our discount ranking. INVA carries the stronger quality grade.
| INVA | NAGE | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $20.77 | $3.53 |
| 12-month range | $18.11–$23.41 | $3.33–$9.88 |
| Sector rank | #60 of 113 Healthcare | #62 of 113 Healthcare |
| Quality grade | B | C |
| Momentum grade | B | — |
| Leverage | Low | Low |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Downtrend |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: INVA fair value analysis · NAGE fair value analysis